Malignant Tumors
Conditions
Brief summary
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis. This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from gene-driven to epigenetic-metabolic-driven early detection.
Detailed description
Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value. Secondary Objectives To determine correlations between serum histone succinylation levels and: Tumor types Tumor stages To statistically analyze associations of serum histone succinylation with: Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables
Interventions
None listed
Sponsors
Yinghua Ji
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Case Group: * Aged ≥18 years, regardless of sex； * Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy； Control Group: * Aged ≥18 years, regardless of sex； * Non-cancer participants enrolled through health screenings；
Exclusion criteria
* Pregnant individuals； * Individuals with serious mental disorders or communication barriers； * Other conditions deemed by investigators to contraindicate study participation；
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors | 2025.08.01-2026.12.31 | Evaluate the positive rate of serum histone succinylation in malignant solid tumor patients versus healthy individuals through Western blot analysis, quantify the percentage difference between the two groups, and thereby validate its potential for early cancer screening |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Define the relationship between histone succinylation modifications in serum and different tumor types as well as tumor staging | 2025.08.01-2026.12.31 | Analyze the relationship between histone succinylation modifications in serum and therapeutic efficacy (specifically surgery, radiotherapy, and systemic therapy)。 |
Contacts
Primary ContactWang Fang Doctor, Graduate Student
Outcome results
None listed